G2TT
来源类型Working Paper
规范类型报告
DOI10.3386/w11724
来源IDWorking Paper 11724
Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts
Tomas J. Philipson; Ernst R. Berndt; Adrian H. B. Gottschalk; Matthew W. Strobeck
发表日期2005-10-31
出版年2005
语种英语
摘要The US Food and drug Administration (FDA) is estimated to regulate markets accounting for about 20% of consumer spending in the US. This paper proposes a general methodology to evaluate FDA policies, in general, and the central speed-safety tradeoff it faces, in particular. We apply this methodology to estimate the welfare effects of a major piece of legislation affecting this tradeoff, the Prescription Drug User Fee Acts (PDUFA). We find that PDUFA raised the private surplus of producers, and thus innovative returns, by about $11 to $13 billion. Dependent on the market power assumed of producers while having patent protection, we find that PDUFA raised consumer welfare between $5 to$19 billion; thus the combined social surplus was raised between $18 to $31 billions. Converting these economic gains into equivalent health benefits, we find that the more rapid access of drugs on the market enabled by PDUFA saved the equivalent of 180 to 310 thousand life-years. Additionally, we estimate an upper bound on the adverse effects of PDUFA based on drugs submitted during PDUFA I/II and subsequently withdrawn for safety reasons, and find that an extreme upper bound of about 56 thousand life-years were lost. We discuss how our general methodology could be used to perform a quantitative and evidence-based evaluation of the desirability of other FDA policies in the future, particularly those affecting the speed-safety tradeoff.
主题Health, Education, and Welfare ; Health ; Public Economics
URLhttps://www.nber.org/papers/w11724
来源智库National Bureau of Economic Research (United States)
引用统计
资源类型智库出版物
条目标识符http://119.78.100.153/handle/2XGU8XDN/569374
推荐引用方式
GB/T 7714
Tomas J. Philipson,Ernst R. Berndt,Adrian H. B. Gottschalk,et al. Assessing the Safety and Efficacy of the FDA: The Case of the Prescription Drug User Fee Acts. 2005.
条目包含的文件
文件名称/大小 资源类型 版本类型 开放类型 使用许可
w11724.pdf(214KB)智库出版物 限制开放CC BY-NC-SA浏览
个性服务
推荐该条目
保存到收藏夹
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Tomas J. Philipson]的文章
[Ernst R. Berndt]的文章
[Adrian H. B. Gottschalk]的文章
百度学术
百度学术中相似的文章
[Tomas J. Philipson]的文章
[Ernst R. Berndt]的文章
[Adrian H. B. Gottschalk]的文章
必应学术
必应学术中相似的文章
[Tomas J. Philipson]的文章
[Ernst R. Berndt]的文章
[Adrian H. B. Gottschalk]的文章
相关权益政策
暂无数据
收藏/分享
文件名: w11724.pdf
格式: Adobe PDF
此文件暂不支持浏览

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。